OXB
Generated by Meeveem AI
"Leading viral vector CDMO enabling life changing cell and gene therapies worldwide"
Oxford
•501 - 1000 Employees
•Contract Research
About OXB
OXB is a global contract development and manufacturing organisation specialising in viral vectors for cell and gene therapy. With over 30 years of experience, the company produces lentiviral and AAV vectors used by pharmaceutical and biotechnology companies to develop treatments for serious diseases. Operating facilities across the UK, France, and the United States, OXB provides end to end services from plasmid design through to commercial scale GMP manufacturing. The company serves clients at every stage, from early proof of concept through to commercialisation. OXB's expertise helps advance therapies addressing previously untreatable conditions, bringing new treatment options to patients. Manufacturing capabilities and regulatory knowledge support translating innovation into accessible treatments.
900
Team Members
1995
Founded
Contract Research
Sector
Hybrid
Work Environment
Our Vision
A world where cell and gene therapies are universally accessible treatment options for patients facing serious diseases, enabled by reliable and scalable viral vector manufacturing supporting innovation across the global biopharmaceutical industry.
Our Mission
OXB enables its clients to deliver life changing therapies to patients around the world.